| Source: |
| Type: type of cell death |
| Situation in which a cell actively pursues a course toward death upon receiving certain stimuli. Cancer is one of the scenarios where too little apoptosis occurs, resulting in malignant cells that will not die. |
| 2906- | LT, | Luteolin, a flavonoid with potentials for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 2909- | LT, | Revisiting luteolin: An updated review on its anticancer potential |
| - | Review, | Var, | NA |
| 2913- | LT, | Luteolin induces apoptosis by impairing mitochondrial function and targeting the intrinsic apoptosis pathway in gastric cancer cells |
| - | in-vitro, | GC, | HGC27 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | GC, | MKN45 |
| 2916- | LT, | Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2346- | LT, | Luteolin suppressed PKM2 and promoted autophagy for inducing the apoptosis of hepatocellular carcinoma cells |
| - | in-vitro, | HCC, | HepG2 |
| 4231- | LT, | Luteolin and its antidepressant properties: From mechanism of action to potential therapeutic application |
| - | Review, | AD, | NA |
| 8346- | Lut, | Lutein inhibits tumor progression through the ATR/Chk1/p53 signaling pathway in non-small cell lung cancer |
| - | vitro+vivo, | NSCLC, | A549 |
| 8345- | Lut, | Lutein inhibits breast cancer cell growth by suppressing antioxidant and cell survival signals and induces apoptosis |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 8348- | Lut, | Lutein inhibits proliferation, invasion and migration of hypoxic breast cancer cells via downregulation of HES1 |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA‑MB‑157 |
| 8349- | Lut, | Lutein Inhibits Cell Growth and Activates Apoptosis via the PI3K/AKT/mTOR Signaling Pathway in A549 Human Non-Small-Cell Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | HCC827 | - | in-vitro, | Nor, | BEAS-2B |
| 8343- | Lut, | Association of Lutein with Cancer: A Systematic Review of the Lutein Effects on Cellular Processes Involved in Cancer Progression |
| - | Review, | Var, | NA |
| 3531- | Lyco, | Lycopene attenuates the inflammation and apoptosis in aristolochic acid nephropathy by targeting the Nrf2 antioxidant system |
| - | in-vivo, | Nor, | NA |
| 3532- | Lyco, | Lycopene alleviates oxidative stress via the PI3K/Akt/Nrf2pathway in a cell model of Alzheimer’s disease |
| - | in-vitro, | AD, | NA |
| 3263- | Lyco, | Lycopene protects against myocardial ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening |
| - | in-vitro, | Nor, | H9c2 | - | in-vitro, | Stroke, | NA |
| 3277- | Lyco, | Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent |
| - | Review, | Var, | NA |
| 8414- | Lyco, | Exploring the Therapeutic Potential of Lycopene: Mechanisms, Biological Activities, and Health Benefits |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 8407- | Lyco, | Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines |
| - | in-vitro, | Pca, | LNCaP |
| 4228- | Lyco, | A review for the pharmacological effect of lycopene in central nervous system disorders |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4777- | Lyco, | Lycopene Inhibits Activation of Epidermal Growth Factor Receptor and Expression of Cyclooxygenase-2 in Gastric Cancer Cells |
| - | in-vitro, | GC, | AGS |
| 4778- | Lyco, | Lycopene exerts cytotoxic effects by mitochondrial reactive oxygen species–induced apoptosis in glioblastoma multiforme |
| - | in-vitro, | GBM, | GBM8401 |
| 4779- | Lyco, | Lycopene Inhibits Reactive Oxygen Species-Mediated NF-κB Signaling and Induces Apoptosis in Pancreatic Cancer Cells |
| - | in-vitro, | PC, | PANC1 |
| 4780- | Lyco, | Potential inhibitory effect of lycopene on prostate cancer |
| - | Review, | Pca, | NA |
| 4783- | Lyco, | Lycopene suppresses gastric cancer cell growth without affecting normal gastric epithelial cells |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | Nor, | GES-1 |
| 4785- | Lyco, | The Protective Anticancer Effect of Natural Lycopene Supercritical CO2 Watermelon Extracts in Adenocarcinoma Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 |
| 4791- | Lyco, | Investigating into anti-cancer potential of lycopene: Molecular targets |
| - | Review, | Var, | NA |
| 4803- | Lyco, | Enhanced cytotoxic and apoptosis inducing activity of lycopene oxidation products in different cancer cell lines |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Melanoma, | A431 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | A549 |
| 4797- | Lyco, | A mechanistic updated overview on lycopene as potential anticancer agent |
| - | Review, | Var, | NA |
| 4795- | Lyco, | Updates on the Anticancer Profile of Lycopene and its Probable Mechanism against Breast and Gynecological Cancer |
| - | Review, | BC, | NA |
| 4794- | Lyco, | Anticancer Effect of Lycopene in Gastric Carcinogenesis |
| - | Review, | GC, | NA |
| 1013- | Lyco, | Lycopene induces apoptosis by inhibiting nuclear translocation of β-catenin in gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 1126- | Lyco, | Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway |
| - | vitro+vivo, | Oral, | NA |
| 5252- | MAG, | Insights on the Multifunctional Activities of Magnolol |
| - | Review, | Var, | NA |
| 8524- | MAG, | Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | CRC, | HCT116 |
| 8519- | MAG, | Magnolol inhibits growth of gallbladder cancer cells through the p53 pathway |
| - | vitro+vivo, | Gall, | NA |
| 8492- | MAG, | Magnolol improves Alzheimer's disease-like pathologies and cognitive decline by promoting autophagy through activation of the AMPK/mTOR/ULK1 pathway |
| - | in-vivo, | AD, | NA |
| 8493- | MAG, | Magnolol upregulates CHRM1 to attenuate Amyloid-β-triggered neuronal injury through regulating the cAMP/PKA/CREB pathway |
| - | in-vitro, | AD, | SH-SY5Y |
| 8497- | MAG, | Magnolol induces apoptosis in MCF-7 human breast cancer cells through G2/M phase arrest and caspase-independent pathway |
| - | in-vitro, | BC, | MCF7 |
| 8498- | MAG, | Induction of apoptosis by magnolol via the mitochondrial pathway and cell cycle arrest in renal carcinoma cells |
| - | in-vitro, | Kidney, | 786-O | - | in-vitro, | RCC, | OS-RC-2 | - | in-vitro, | Nor, | HK-2 |
| 8505- | MAG, | Role of magnolol in gastrointestinal cancers: Recent trends and future perspectives |
| - | Review, | GC, | NA |
| 8516- | MAG, | Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma |
| - | in-vitro, | Melanoma, | NA |
| 8506- | MAG, | Magnolia officinalis Lignans induce apoptosis and epigenetic reprogramming via the miR-148a-3p/DNMT-1/UTF-1 axis in pancreatic cancer cells |
| - | in-vitro, | PC, | Panc02 | - | in-vitro, | PC, | MIA PaCa-2 |
| 4517- | MAG, | Mitochondrion-targeted magnolol derivatives exert synergistic anticancer activity by modulating energy metabolism and tumor microenvironment |
| - | vitro+vivo, | Var, | NA |
| 4533- | MAG, | Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways |
| - | in-vitro, | GC, | SGC-7901 |
| 4515- | MAG, | Magnolol as a Potential Anticancer Agent: A Proposed Mechanistic Insight |
| - | Review, | Var, | NA |
| 4516- | MAG, | Magnolol Induces Apoptosis and Suppresses Immune Evasion in Non-small Cell Lung Cancer Xenograft Models |
| - | in-vivo, | NSCLC, | NA |
| 4534- | MAG, | Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | COLO205 |
| 4536- | MAG, | Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis |
| - | in-vitro, | Liver, | HepG2 | - | in-vivo, | CRC, | COLO205 |
| 4537- | MAG, | Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action |
| - | in-vivo, | Melanoma, | NA | - | in-vitro, | Melanoma, | A431 |
| 4531- | MAG, | Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway |
| - | in-vitro, | CRC, | HCT116 |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:14 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid